Abstract:The analgesic effects of the rat in response to electroacupuncture (EA) or low-dose morphine (3 mg/kg) show marked individual variations. In the midbrain periaqueductal gray (PAG) of the rat, the content of the neuropeptide cholecystokinin octapeptide (CCK-8) was found to be significantly higher in the low responder (LR) rats as compared to that in the high responders (HR). Since PAG has been shown to be a strategic site for CCK-8 to exert an anti-opioid action, a high CCK content in PAG may account for the low analgesic responsiveness to EA and morphine. In order to block the expression of the gene encoding preproCCK in the brain, antisense CCK expression vector pSV2-CCKAS was microinjected into the lateral cerebral ventricle of the rat, leading to a decrease of the CCK-mRNA as well as the CCK-8 content in rat brain. This effect started 4 days after the intracerebroventricular (i.c.v.) injection of the antisense expression vector, and lasted no more than 1 week. This procedure was shown to be very effective in converting LR rats into HR for EA analgesia and morphine analgesia, and also delayed the development of tolerance elicited by prolonged EA stimulation or repeated morphine administration. The time course of the augmentation of opioid analgesia (4–6 days after the i.c.v. injection of the expression vector) paralleled the decrease of the brain CCK-8 content. The results argue that blocking the CCK gene expression in the brain may tilt the balance between opioid and anti-opioid peptides in favor of the former, thus strengthening the EA analgesia and morphine analgesia, and delaying the development of opioid tolerance.

Is cholecystokinin octapeptide (CCK-8) a candidate for endogenous antiopioid substrates?

Cholecystokinin Octapeptide (CCK-8) Antagonizes Morphine Analgesia in Nucleus Accumbens of the Rat Via the CCK-B Receptor

Cholecystokinin Octapeptide Induces Endogenous Opioid-Dependent Anxiolytic Effects in Morphine-Withdrawal Rats

Cholecystokinin Octapeptide Antagonized Opioid Analgesia Mediated by Μ- and Κ- but Not Δ-Receptors in the Spinal Cord of the Rat

Cholecystokinin octapeptide (CCK-8: A negative feedback control mechanism for opioid analgesia

Cholecystokinin Octapeptide Reverses the Inhibitory Effect Induced by Electroacupuncture on C-Fiber Evoked Discharges

Electroacupuncture-induced Release of Cholecystokinin Octapeptide Mediated by Spinal Μ- and К-Opioid Receptors

CCK RECEPTOR ANTAGONIST L-365,260 POTENTIATED ELECTROACUPUNCTURE ANALGESIA IN WISTAR RATS BUT NOT IN AUDIOGENIC EPILEPTIC RATS

CCKB receptor antagonist L365,260 potentiates the efficacy to and reverses chronic tolerance to electroacupuncture-induced analgesia in mice

Cholecystokinin-Octapeptide Antagonizes Morphine Analgesia in Periaqueductal Gray of the Rat

Effects of CCK-8 on the Reinstatement of Morphine-Induced CPP and Expression of Behavioral Sensitization in Rats

Antagonism of the Suppressive Effect of Morphine on Rat Brain Synaptosomal ~(45)ca Uptake by Cholecystokinin Octapeptide

ANTAGONISTIC EFFECT OF CCK-8 ON MORPHINE-INHIBITED ELECTRICAL AND CONTRACTILE ACTIVITIES OF RAT JEJUNUM IN VITRO

Cholecystokinin octapeptide antagonized the effect of NDAP on CaM in rat dorsal spinal synaptosome

Cholecystokinin-B Receptor Antagonists Attenuate Morphine Dependence and Withdrawal in Rats

Cholecystokinin Antisense RNA Increases the Analgesic Effect Induced by Electroacupuncture or Low Dose Morphine: Conversion of Low Responder Rats into High Responders

Synergistic Effect of Cholecystokinin Octapeptide and Angiotensin II in Reversal of Morphine Induced Analgesia in Rats

Involvement of Endogenous Cholecystokinin in Tolerance to Morphine Antinociception in the Nucleus Accumbens of Rats

Modification by Cholecystokinin Octapeptide of the Binding of?-, ?-, and <sub>K</sub>-Opioid Receptors

Potentiation of Electroacupuncture-Induced Analgesia by Cck-B Antagonist L-365, 260 in Wistar Rats but Not in Acoustically-Evoked Epileptic Rats

The Possible Involvement of Endogenous Ligands for Mu-, Delta- and Kappa-Opioid Receptors in Modulating Morphine-Induced CPP Expression in Rats